2026-04-13T02:11:45Zhttps://recercat.cat/oai/request

oai:recercat.cat:10256/285562026-03-27T00:12:40Zcom_2072_452966com_2072_2054col_2072_452968

00925njm 22002777a 4500 dc Gómez Bizarro, Anna author 2025-07 Given the growing interest in multi-domain biotechnological drugs due to their potential to improve the pharmacokinetic and pharmacodynamic properties of conventional protein drugs, this literature review aims to provide a detailed or comprehensive description of the most recent advances in the development of these drugs. First, it describes what fusion proteins, multi-domain drugs, pharmacokinetics and pharmacodynamics are, mentioning the properties that these drugs can improve. Next, it describes the functional domains that can form part of these molecules, such as domains that allow them to cross physiological barriers, protein transduction domains, and receptor-binding domains, among others, explaining the function of each and the mechanisms by which they exert their therapeutic action. This paper also reviews the most relevant studies in this field, as well as the current and potential therapeutic applications of these drugs in pathologies such as cancer and neurodegenerative disorders such as Alzheimer. Finally, the main limitations facing these types of therapies are analysed, including structural stability, immunogenicity and complexity in their production. This analysis allows us to assess the emerging role of multi-domain drugs in biomedical innovation and their future prospects in the design of more effective and personalised therapies 3 https://hdl.handle.net/10256/28556 Biotecnologia farmacèutica Medicaments biològics Biopharmaceutical Pharmaceutical biotechnology Darrers avenços en el desenvolupament de fàrmacs biotecnològics multi-domini